Literature DB >> 8412264

Talc pleurodesis. Experience with 360 patients.

D Weissberg1, I Ben-Zeev.   

Abstract

Talc was used intrapleurally for the creation of pleural adhesions in 360 patients. The indications for use were malignant pleural effusion in 169 patients, benign effusions in 41, recurrent pneumothorax in 122, empyema in 19, and chylothorax in 9. Of 336 patients available for follow-up, excellent results (complete pleurodesis) were achieved in 284 patients (84.5%), fair results in 28 (8.3%), and poor results (no adhesions) in 24 (7.2%). The results were best in empyema (100%) and better in pneumothorax than in pleural effusions. With repeat talc insufflation, the results were improved to excellent in more than 90% of the patients. Talc is the most effective and least expensive agent for creation of pleural adhesions. Its use is simple and easily tolerated by the patients. Because of the carcinogenic effect of asbestos, purified talc that is free of asbestos fibers must be used.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412264

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model.

Authors:  Yasunori Iwasaki; Shinzo Takamori; Masahiro Mitsuoka; Masaki Kashihara; Tatsuya Nishi; Daigo Murakami; Ryoichi Matsumoto; Hiroharu Mifune; Yuji Tajiri; Yoshito Akagi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-12

3.  Acute empyema with intractable pneumothorax associated with ruptured lung abscess caused by Mycobacterium avium.

Authors:  Katsuyuki Asai; Norikazu Urabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-06-15

Review 4.  Bilateral chylothorax: an unusual complication of cervical rib resection.

Authors:  Jaymin B Morjaria; Imran Aslam; Brian Johnson; Michael A Greenstone; Jack A Kastelik
Journal:  Ther Adv Chronic Dis       Date:  2015-01       Impact factor: 5.091

5.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

6.  Changes in the pleural cavity by pleurodesis using talc or OK-432: an experimental study.

Authors:  Fumihiko Muta; Shinzo Takamori; Toshihiro Matsuo; Yasunori Iwasaki; Koichi Yoshiyama; Kazuo Shirouzu
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

7.  Effective and rapid technique to ensure uniform talc pleurodesis.

Authors:  Zeena Makhija; Ranjit Deshpande; Michael T Marrinan
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-11-11

8.  Talc Pleurodesis With Intense 18F-FDG Activity But No 68Ga-DOTA-TATE Activity on PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Ulas Bagci; Nicholas J Patronas; Constantine A Stratakis
Journal:  Clin Nucl Med       Date:  2015-10       Impact factor: 7.794

9.  FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.

Authors:  Giovenzio Genestreti; Andrea Moretti; Sara Piciucchi; Noemi Giovannini; Riccardo Galassi; Emanuela Scarpi; Marco Angelo Burgio; Dino Amadori; Stefano Sanna; Venerino Poletti; Federica Matteucci; Giampaolo Gavelli
Journal:  J Cancer       Date:  2012-06-01       Impact factor: 4.207

10.  Does pleurodesis for pleural effusions give bright ideas about the agents for hydrocele sclerotherapy?

Authors:  U Yilmaz; O Ekmekçioğlu; A Tatlişen; D Demirci
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.